Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark R Nehler, MD
The Univesity of Colorado at Denver
Principal Investigator - William R Hiatt, MD
Colorado Prevention Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Colorado at Denver
Aurora, Colorado, United States
- Denver Health and Hospital Authority (dhha)
Denver, Colorado, United States
- Department of Veteran Affairs Medical Center
Denver, Colorado, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2008
- Primary completion
- 30 Jun 2009
- Completion
- 30 Jun 2009
- Last update posted
- 15 Aug 2014
- Registered enrollment
- 0
- Registry id
- NCT00657514
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.